Fig. 3: Clinical annotation of putative fusions in EGFR mutant lung cancer.
From: Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
a Clinical course of patients with fusions, which were detected by DNA-based next generation sequencing (NGS) OncoPanel, following treatment with first or third generation (1G or 3G) EGFR tyrosine kinase inhibitors (TKIs). Asterisks indicate samples that did not undergo initial evaluation by OncoPanel. Bar charts show total durations of EGFR-TKI treatment before and after the fusions were detected. RNA from these samples were submitted for further RNA sequencing (blue). b Clinical course of patients with fusions that were detected prior to treatment with EGFR-TKI.
